

## SUBJECT INDEX VOLUME 27

- A**
- 5-HT receptors, 171
  - 5-HT, 869
  - 5-HT<sub>1A</sub> agonist, 421
  - 5-HT<sub>1A</sub> antagonist, 421
  - 5-HT<sub>1A</sub> receptor agonism, 430
  - 5-HT<sub>1A</sub> receptor knockout mice, 380
  - 5-HT<sub>1A</sub> Receptors, 301
  - 5-HT<sub>1A</sub> Receptors, 349
  - 5-HT<sub>2A</sub> and 5-HT<sub>2C</sub> receptors, 576
  - 5-HT<sub>2A</sub> receptor antagonism, 430
  - 5-HT<sub>2C</sub> receptor antagonism, 430
  - 8-OH-DPAT, 993
  - Acamprosate, 596
  - Acetylcholine, 182
  - Acetyl-L-carnitine, 410
  - ACPC, 727
  - ACTH, 442, 470
  - Addiction, 727, 889, 924, 1027
  - Adenosine, 629
  - Adolescence, 212
  - Adults, 655
  - Affective disorders, 638, 792, 874
  - Aggression, 171, 646
  - Aging, 663
  - Alcohol, 596
  - Alprazolam, 260
  - Alzheimer's disease, 646
  - Amidation, 55
  - Amino acids, 852
  - Amisulpride, 1071
  - Amitriptyline, 554
  - AMPA, 826
  - Amphetamine, 225, 930, 970, 1036
  - Amygdala, 1036
  - Anandamide, 980
  - Animal model, 1
  - Anpirtoline, 171
  - Antidepressant drug development, 319
  - Antidepressant drugs, 357
  - Antidepressant response, 120
  - Antidepressant treatment, 874
  - Antidepressant, 237, 319, 587, 914, 939, 949
  - Antipsychotic agents, 906
  - Antipsychotic drugs, 105
  - Antipsychotic, 1, 691, 930, 1071
  - Antisaccade, 1056
  - Antisense oligodeoxyribonucleotides, 554
  - Anxiety, 25, 85, 194, 357, 371, 380, 782, 1036
  - Anxiolytic drugs, 357
  - Apomorphine, 980
  - Applied psychology, 279
  - Aripiprazole, 248
  - Assay, 663
  - Association regions, 672
  - Associative, 924
  - Atomoxetine, 699
  - Attention deficit hyperactivity disorder, 607, 655, 699
  - Attention deficit, 400
  - Attention, 712, 993
  - Atypical antipsychotic, 1071
  - Auditory, 862
  - Augmentation, 620, 906
  - Autoimmune disorders, 939
  - Autoradiography, 826
  - Autoreceptors, 301
  - Axiolytic, 194
- B**
- Basal ganglia, 92, 143, 453
  - Basolateral nucleus of the amygdala, 744
  - BDNF mRNA, 133
  - Bed nucleus of stria terminalis, 25
  - Behavior, 380, 691, 813
  - Behavioral and psychological symptoms of dementia, 646
  - Benzodiazepines, 357
  - Bipolar disorder, 620, 792, 834
  - Bradykinesia, 684
  - Brain, 92, 309, 672
- C**
- Caffeine, 182
  - Calcium, 565
  - cAMP, 939
  - Candidate genes, 607
  - Carbenoxolone, 980
  - Cat, 72
  - Catecholamine, 293
  - Caudate-putamen, 143
  - Cholecystokinin, 663
  - Cingulate cortex, 826
  - Clearance, 293
  - Clinical methodology, 319
  - Clinical response, 1050
  - Clinical trial, 319
  - Clomipramine, 554
  - Clozapine, 143, 152, 534, 1050
  - Cocaine abuse, 35
  - Cocaine, 542, 576, 970
  - Cognition, 596
  - Cognitive function, 479
  - Componential behavioral approach, 319
  - Conditioning, 203, 225, 518, 924, 1006
  - Connectivity, 672
  - Context, 1006
  - Cordance, 120
  - Corticosterone, 756
  - Cortisol, 309, 442, 470, 834, 1041
  - Craving, 924
  - CREB, 565
  - CRF, 194
  - CRH, 756
  - Cross-sensitization, 970
  - Current density, 638
  - Cyclic AMP, 587
  - Cytoskeleton, 55
- D**
- D<sub>1</sub> Dopamine receptor, 970
  - D<sub>1</sub> receptors, 35
  - D<sub>2</sub> dopamine receptor; 248
  - D<sub>2</sub> receptor isoforms, 723
  - D<sub>2</sub> receptors, 35, 72
  - d-Amphetamine, 813
  - D-cycloserine, 906
  - Delayed alternation, 47
  - Dentate gyrus, 133
  - Depression, 12, 120, 792, 852, 914, 939
  - Depressive disorder, 1041
  - Desipramine, 914
  - Development, 47, 309, 672
  - DEX/CRH Test, 470
  - DHPG, 293
  - Diazepam, 380
  - Dopamine, 35, 72, 92, 163, 182, 410, 518, 565, 691, 699, 889, 949, 1036
  - Dopamine agonist, 248
  - Dopamine D<sub>3</sub> receptors, 105
  - Dopamine receptors, 607
  - Dopamine release, 430
  - Dopamine transporter, 607
  - Dopamine transporter gene, 655
  - Dorsal raphe nucleus, 349
  - Dorsolateral prefrontal cortex, 638
  - Driving, 260
  - Drug aversion, 727
  - Drug pre-exposure, 970
  - Drug reward, 727
  - Drug self-administration, 1006
  - Drugs of abuse, 565
  - Dual diagnosis, 889
- E**
- ECT, 55
  - EEG, 120
  - EEG topography, 462
  - Electroencephalography, 1016
  - Electrophysiology, 723
  - Elevated plus-maze, 357, 371
  - Elk-1, 565
  - EPSC, 329
  - ERK, 565
  - Escape deficit, 410
  - Estradiol, 800
  - Estrogen, 12
  - Estrus cycle, 85
  - Ethanol, 391, 442
  - Event related potentials, 629
  - Event-related magnetic field, 862
  - Eye movements, 1056
- F**
- Family history, 834
  - Family history of alcoholism, 442
  - Fear, 357, 744, 1036
  - Flesinoxan, 380
  - Fluoxetine, 914
  - fMRI, 282
  - Footshock stress, 133
  - Fos expression, 699

Fos, 565  
 Fox odor, 744  
 Free-choice drinking, 212  
 Frontal cortex, 203  
 Frontal, 672  
 Frustration, 171  
 Fusiform, 282

## G

G proteins, 499  
 GABA<sub>B</sub> receptors antagonist, 960  
 Galanin, 25, 349  
 Gamma-hydroxybutyrate, 960  
 Gap junction, 980  
 GEF, 55  
 Gene knockout, 587  
 Gene knockout mouse, 914  
 Genetics, 655  
 Gerbil, 357, 371  
 Gi-proteins, 554  
 Glucocorticoid, 309  
 Glutamate, 906  
 Glutamatergic neuron, 329  
 GR127935, 171  
 Grooming, 930, 980  
 Growth hormone, 301, 1041

## H

Haloperidol, 143, 152, 430, 534, 684, 930  
 Hamilton Depression Rating Scale, 852  
 Handling stress, 163  
 Haplotype-based haplotype relative risk, 607  
 Herbal medicine, 279  
 Hippocampal slices, 960  
 Hippocampus, 1, 133, 349, 889, 930  
 Hormone replacement therapy, 12  
 HPA axis, 25, 442  
 HPA system, 470  
 Human, 499, 800, 813  
 Hyperactivity, 400  
 Hyperthermia, 380  
 Hyperventilation, 85  
 Hypothalamic-pituitary-adrenal axis, 939  
 Hypothalamus, 301

## I

Immunolabeling, 499  
 Imprinting, 607  
 Impulsive behavior, 421  
 Impulsivity, 171, 813  
 In situ hybridization, 152, 906  
 In vivo microdialysis, 237  
 Intracellular recordings, 960  
 Ipsapirone, 270

## K

Kainate receptors, 826  
 Ketanserin, 993  
 Knock-out, 869

## L

Lithium, 756  
 Lithium augmentation, 470  
 Locomotion, 576, 930  
 Locomotor activity, 349  
 Lorazepam, 282  
 L-thyroxine, 620

## M

M40, 25  
 Magnetic resonance imaging, 792  
 Magnetoencephalography (MEG), 862  
 Maintenance treatment, 620  
 Major depression, 470, 638  
 Male rats, 133  
 Maternal deprivation, 756  
 Maternal separation, 518  
 mCPP, 993  
 MDMA, 993  
 Medial prefrontal cortex, 163, 430, 744  
 Medication resistance, 638  
 Memory, 260, 279, 534, 993  
 Mesolimbic, 518  
 Methamphetamine, 453  
 Methylphenidate, 163, 400, 699  
 Mice, 212, 587  
 Microdialysis, 163, 182, 349, 691, 699, 949  
 Middle-latency auditory magnetic field (MAEF), 862  
 Molecular genetics, 105  
 Monoamines, 237, 1036  
 Monoamine oxidase inhibitors (MAOI), 462  
 Mood, 834, 852  
 Mood disorders, 792, 939, 1016  
 Morphine, 518  
 Motor activity, 980  
 Movement disorder, 92  
 mRNA, 499  
 Multiple drug resistance pump, 939  
 Myelin, 672

## N

Naloxonazine, 391  
 Naltrexone, 391, 596  
 Naltrindole, 391  
 Natural reward, 727  
 NCS-382, 960  
 Negative symptoms, 479  
 Neonatal lesion, 1, 47  
 Neural networks, 672  
 Neuroactive steroids, 874  
 Neurochemical pathology, 646  
 Neuroendocrinology, 470  
 Neuroimaging, 782, 792  
 Neurokinin, 329  
 Neurokinin NK1 receptor, 371  
 Neurokinin-1-receptor, 1041  
 NGFI-B, 400  
 Nicotine, 212, 270, 479, 534, 684, 712, 1056  
 NK<sub>1</sub> receptor antagonists, 371  
 NK<sub>1</sub> receptors, 329  
 NMDA, 826  
 NonREM, 869  
 Noradrenaline, 691  
 Norepinephrine, 163, 699, 949  
 Novelty seeking, 225  
 Novelty, 380  
 NPY, 55, 756  
 Nucleus accumbens, 35, 182, 430, 889, 1027  
 Nucleus accumbens shell, 410

## O

Occasion setting, 1006  
 Olanzapine, 143  
 Olfactory tubercle, 203  
 Ondansetron, 542  
 Onset of drug action, 319  
 Opioid antagonists, 391  
 Opioid peptide, 203  
 Opioids, 518  
 Opponent processes, 542

Oral behaviors, 980  
 Oral self-administration, 212  
 Orbitofrontal cortex, 782

## P

P50, 629  
 Panic attacks, 663  
 Panic disorder, 85, 270  
 Parkinson's disease, 723  
 Pavlovian, 924  
 Performance, 260  
 Pertussis toxin, 554  
 Pharmacodynamics, 596  
 Pharmacogenetics, 105  
 Pharmacogenomics, 105  
 Pharmacokinetics, 596  
 Phosphodiesterase 4D (PDE4D), 587  
 Pigeon, 421  
 Pituitary-adrenal, 194  
 Place conditioning, 727  
 Plasma concentration, 663  
 Plasma levels, 1050  
 Positron Emission Tomography (PET), 72, 248, 782  
 Posterior cingulate cortex, 782  
 Postmortem brain, 499  
 Prefrontal, 120  
 Prefrontal cortex, 47, 182, 874  
 Premenstrual dysphoria, 85  
 Prepulse inhibition, 1, 400, 765  
 Primate, 12  
 Priming, 282  
 Progesterone, 12, 800  
 Progressive ratio schedule of reinforcement, 970  
 Prolactin, 301, 800  
 Prophylaxis resistance, 620  
 Proton magnetic resonance spectroscopy, 453  
 Psychological stress, 133  
 Psychology, 279  
 Psychomotor, 260  
 Psychopharmacology, 279, 282  
 Purinergic system, 629

## Q

Quantitative Trait Analysis, 655  
 Quantitative Trait Locus (QTL), 765

## R

[<sup>11</sup>C]raclopride, 72, 248  
 Raclopride, 1006  
 Radial-arm maze, 534  
 Radiotelemetry, 380  
 Raphe, 329  
 Rat, 85, 712, 727, 756  
 Reboxetine, 237, 699  
 Receptor binding, 663  
 Receptor occupancy, 248  
 Recombinant congenic mouse strains, 765  
 Regional differences, 462  
 Reinforcement, 171, 1027  
 Reinstatement, 1006  
 Relapse, 391, 1006  
 REM sleep, 462, 843, 1016  
 Response prediction, 120  
 Reuptake, 237  
 Reward, 1027  
 R-Fluoxetine, 949  
 Rhesus monkey, 35  
 Rigidity, 684  
 Risperidone, 143, 534, 1071

RNA messenger, 906  
Rolipram, 587

## S

SCH 23390, 970, 1006  
Schizoaffective disorder, 620  
Schizophrenia, 1, 105, 143, 152, 248, 293, 309,  
479, 629, 672, 684, 723, 765, 826, 889,  
1050, 1056, 1071  
Scopolamine, 282  
Self-administration, 542, 576, 970  
Sensitization, 225, 542, 924, 970  
Sensorimotor gating, 765  
Sensory gating, 629  
Serial reaction time, 712  
Serotonergic reuptake inhibitor, 782  
Serotonin, 12, 171, 270, 301, 329, 349, 410,  
576, 646, 800, 834, 843, 852, 862, 949, 1016  
Serotonin transporter, 914  
Short-term memory, 279  
Single nucleotide polymorphism, 105  
Sleep, 843, 869, 1041  
Sleep deprivation, 869  
Slow-wave activity, 462  
Smoking, 270, 479  
Smooth pursuit, 1056  
Sniffing stereotypy, 980  
Social instigation, 171  
Sodium lactate, 85

Spillover, 293  
SSRI, 421  
Startle response, 765  
State dependence, 727  
Stereology, 143  
Stimulation intensity, 638  
Stress, 25, 194, 203, 237, 309, 410, 442, 756  
Stress-induced hyperthermia, 380  
Striatum, 35, 92  
Subjective Effect, 813  
Substance P, 1041  
Substantia nigra, 723  
Sucrose, 171  
Suicide, 499  
Supraphysiological, 620  
Sustained attention, 1056

## T

Tachycardia, 380  
Tachykinin, 371  
Tardive dyskinesia, 105  
Temporal, 672  
Testosterone, 800  
Theophylline, 629  
Theta activity, 462  
TMS, 874  
Tolerance, 712  
Tourette syndrome, 92  
Transcranial magnetic stimulation, 638, 874

Transcription factors, 152  
Transgenic, 869  
Transmission Disequilibrium Test, 607  
Tremor, 684  
Tricyclic antidepressants, 554  
Tritium-labeled norepinephrine, 293  
Tryptophan, 843  
Tryptophan depletion, 834, 852, 862  
Tumor necrosis factor alpha, 939

## U

Unipolar disorder, 792  
Unipolar major depressive disorder, 620

## V

Ventral hippocampus, 47  
Ventral tegmental area, 723, 744, 970  
Voltammetry, 72

## W

Weaning, 225  
White matter, 672  
Withdrawal, 203, 542  
Working memory, 47